Robert A Kyle

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation
    Robert A Kyle
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:1958-66. 2006
  2. pmc Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients
    John P Bida
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:685-93. 2009
  3. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
  4. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
  5. ncbi request reprint Focal and segmental glomerulosclerosis and plasma cell proliferative disorders
    David Dingli
    Division of Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:278-82. 2005
  6. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
  7. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
  8. pmc Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
    Kristen Detweiler-Short
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:737-40. 2010
  9. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
  10. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011

Detail Information

Publications118 found, 100 shown here

  1. ncbi request reprint Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation
    Robert A Kyle
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:1958-66. 2006
    ..The importance of obtaining a complete response (CR) in multiple myeloma (MM) treated with chemotherapy is unclear...
  2. pmc Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients
    John P Bida
    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:685-93. 2009
    ..To systematically study the association of monoclonal gammopathy of undetermined significance (MGUS) with all diseases in a population-based cohort of 17,398 patients, all of whom were uniformly tested for the presence or absence of MGUS...
  3. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  4. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  5. ncbi request reprint Focal and segmental glomerulosclerosis and plasma cell proliferative disorders
    David Dingli
    Division of Hematology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 46:278-82. 2005
    ..FSGS can be caused by a variety of conditions, but it has been reported rarely in association with a plasma cell disorder...
  6. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  7. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  8. pmc Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
    Kristen Detweiler-Short
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:737-40. 2010
    ..Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM...
  9. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  10. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  11. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  12. pmc Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition
    Terry M Therneau
    Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
    Mayo Clin Proc 87:1071-9. 2012
    ..To determine the incidence of monoclonal gammopathy of undetermined significance (MGUS) in the general population and to estimate the duration of occult MGUS before first diagnosis...
  13. doi request reprint Serum uric acid: novel prognostic factor in primary systemic amyloidosis
    Shaji Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:297-303. 2008
    ..To determine the prognostic value of serum uric acid (UA) in patients with primary systemic (light chain) amyloidosis (AL)...
  14. pmc Morbidity and mortality among older individuals with undiagnosed celiac disease
    Jonathan D Godfrey
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 139:763-9. 2010
    ..Outcomes of undiagnosed celiac disease (CD) are unclear. We evaluated the morbidity and mortality of undiagnosed CD in a population-based sample of individuals 50 years of age and older...
  15. ncbi request reprint Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  16. doi request reprint Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy
    Taxiarchis V Kourelis
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 89:302-5. 2014
    ..05). All patients who progressed and were rechallenged with LenDex responded. These analyses illustrate that discontinuation of lenalidomide after 1 year among those patients achieving a ≥VGPR can result in long-term disease control...
  17. doi request reprint Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies
    Samih H Nasr
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Kidney Dis 59:786-94. 2012
    ..Renal involvement is common in multiple myeloma. In this study, we examined kidney biopsy findings in patients with multiple myeloma and correlated them with their clinical renal and hematologic characteristics...
  18. pmc Trends and outcomes of modern staging of solitary plasmacytoma of bone
    Rahma Warsame
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:647-51. 2012
    ..The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up...
  19. ncbi request reprint Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 103:3960-3. 2004
    ..Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL...
  20. ncbi request reprint Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 356:2582-90. 2007
    ..Prognostic factors for the progression and outcome of this disease are unclear...
  21. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  22. doi request reprint Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013
    Joseph R Mikhael
    Division of Hematology Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 88:360-76. 2013
    ..This consensus statement reflects recommendations from more than 20 Mayo Clinic myeloma physicians, providing a practical approach for newly diagnosed patients with myeloma who are not enrolled in a clinical trial...
  23. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  24. ncbi request reprint Bone marrow angiogenesis in multiple myeloma: effect of therapy
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:665-71. 2002
    ..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy...
  25. ncbi request reprint Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:3751-7. 2004
    ..Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL...
  26. pmc Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features
    Shaji Kumar
    Division of Hematology and Internal Medicine, Department of Laboratory Medicine and Pathology, Department of Biochemistry, Mayo Clinic, Rochester, MN, USA
    Blood 116:5126-9. 2010
    ..9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL...
  27. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  28. ncbi request reprint Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    ..To determine the clinical and laboratory features of newly diagnosed multiple myeloma...
  29. pmc Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma
    Shirshendu Sinha
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 148:853-8. 2010
    ..Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome...
  30. ncbi request reprint Prevalence of monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 354:1362-9. 2006
    ..We used sensitive laboratory techniques to ascertain the prevalence of MGUS in a large population in a well-defined geographic area...
  31. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  32. pmc Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome
    Trista Stankowski-Drengler
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:431-4. 2010
    ..In summary, serum immunoglobulin profiles are unique in POEMS syndrome as compared with other plasma cell disorders...
  33. pmc Immunoglobulin free light chains and solitary plasmacytoma of bone
    David Dingli
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 108:1979-83. 2006
    ..5 g/dL) or higher (high risk, n = 18). The corresponding progression rates at 5 years were significantly different in the low, intermediate, and high groups: 13%, 26%, and 62%, respectively (P < .001)...
  34. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  35. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  36. pmc Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Shaji Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 119:2100-5. 2012
    ..Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers...
  37. pmc Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
    Prashant Kapoor
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:532-7. 2010
    ..This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents...
  38. ncbi request reprint Treatment of multiple myeloma: an emphasis on new developments
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Med 38:111-5. 2006
    ..Patients with relapsed or refractory disease may be treated with dexamethasone, thalidomide and dexamethasone, bortezomib (Velcade, PS-341), or lenalidomide (Revlimid, not yet approved by the Food and Drug Administration)...
  39. pmc Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
    Angela Dispenzieri
    Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Lancet 375:1721-8. 2010
    ..The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS...
  40. pmc The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
    Cheng E Chee
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:2617-8. 2009
    ..2 years vs 2.3 years, respectively; P = .01)...
  41. doi request reprint Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Clin Oncol 27:5008-14. 2009
    ..We report, to our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose dexamethasone for the treatment of relapsed or refractory multiple myeloma...
  42. pmc Screening panels for detection of monoclonal gammopathies
    Jerry A Katzmann
    Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA
    Clin Chem 55:1517-22. 2009
    ..Although there are several reports on the relative diagnostic contribution of these assays, none has looked at the tests singly and in combination for the various plasma cell proliferative disorders (PCPDs)...
  43. ncbi request reprint Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1047-53. 2006
    ..These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits...
  44. pmc Clinical implication of centrosome amplification in plasma cell neoplasm
    Wee J Chng
    Division of Hematology Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA
    Blood 107:3669-75. 2006
    ....
  45. pmc Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:4050-3. 2005
    ..Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma...
  46. pmc Outcomes of patients with POEMS syndrome treated initially with radiation
    Michael S Humeniuk
    Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 122:68-73. 2013
    ..The presence of 3 lesions compared with 1 or 2 did not increase risk for treatment failure. Among selected patients with POEMS syndrome, radiation produces durable, meaningful responses. ..
  47. pmc Progression in smoldering Waldenstrom macroglobulinemia: long-term results
    Robert A Kyle
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4462-6. 2012
    ..Patients with SWM should be followed and not treated until symptomatic WM develops. Treatment on a clinical trial for those at greatest risk of progression should be considered...
  48. pmc Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    Shaji Kumar
    Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 30:989-95. 2012
    ..However, long-term outcome is dependent on the underlying plasma cell clone, and incorporation of clonal characteristics may allow for better risk stratification...
  49. ncbi request reprint Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Amyloid 10:257-61. 2003
    ..Median time on the study was 72 days, range was 25 to 333 days. All 12 have withdrawn from the study (side-effects, 6; progression, 4; and death, 2 patients). AL patients do not tolerate high dose thalidomide...
  50. ncbi request reprint Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays
    Jerry A Katzmann
    Division of Clinical Biochemistry and Immunology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1575-8. 2006
    ..To determine the relative diagnostic contribution of urine assays as part of the screening algorithm for monoclonal gammopathies...
  51. pmc Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  52. pmc A novel report of cig-FISH and cytogenetics in POEMS syndrome
    Alan H Bryce
    Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 83:840-1. 2008
    ..Three patients had IgH translocation t(11;14)(q13;q32). No abnormalities were seen at 17p13(p53). The monosomy 13 is in line with other plasma cell disorders while the low prevalence of hyperdiploidy and abnormalities at 14q32 is unique...
  53. ncbi request reprint Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 102:3759-64. 2003
    ..5 g/dL or less, 26% with 1.5 g/dL, 34% for 2.0 g/dL, and 41% for more than 2.5 g/dL...
  54. ncbi request reprint International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...
  55. doi request reprint History of multiple myeloma
    Robert A Kyle
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Recent Results Cancer Res 183:3-23. 2011
    ..The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide...
  56. pmc Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
    Angela Dispenzieri
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Blood 111:785-9. 2008
    ..The serum immunoglobulin FLC ratio is an important additional determinant of clinical outcome in patients with SMM...
  57. pmc Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 106:812-7. 2005
    ....
  58. pmc Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies
    Jerry A Katzmann
    Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Clin Chem 57:1687-92. 2011
    ....
  59. ncbi request reprint Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia
    Irene M Ghobrial
    Division of Hematology, Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:158-64. 2006
    ..Beta2-microglobulin > or =4 mg/l was associated with a threefold increase in the risk of death when added to the prognostic model. We describe a simple prognostic model for overall survival for newly diagnosed patients with WM...
  60. ncbi request reprint Clinical course of patients with relapsed multiple myeloma
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:867-74. 2004
    ..To study the clinical course of patients with multiple myeloma (MM) that relapses after initial therapy...
  61. pmc Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma
    Alexandra J Greenberg
    Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 157:472-5. 2012
    ..We saw no increased risk in relatives of HC-MGUS probands. We conclude that the prevalence of LC-MGUS is significantly higher among 1° relatives of MM probands compared to the reference population...
  62. doi request reprint Immunoglobulin D amyloidosis: a distinct entity
    Morie A Gertz
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 119:44-8. 2012
    ..The overall survival of these patients does not appear to be different from that of patients who have light-chain amyloidosis associated with another monoclonal protein...
  63. pmc The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 115:2155-64. 2009
    ....
  64. pmc Improved survival in multiple myeloma and the impact of novel therapies
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2516-20. 2008
    ..8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis...
  65. ncbi request reprint Clinical and biologic implications of recurrent genomic aberrations in myeloma
    Rafael Fonseca
    Mayo Cinic Division of Hematology, Department of Laboratory Medicine, Rochester, MN 55905, USA
    Blood 101:4569-75. 2003
    ..More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations...
  66. ncbi request reprint Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
    Cynthia X Ma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 104:40-2. 2004
    ..In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process...
  67. ncbi request reprint Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 127:308-10. 2004
    ..The presence of an abnormal kappa/lambda FLC ratio in the serum was associated with a higher risk of MGUS progression (relative risk 2.5; 95% confidence interval: 1.6-4.0; P < 0.001)...
  68. ncbi request reprint Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:827-30. 2003
    ..008). The prognostic value of circulating PBPCs may help select treatment for patients with AL...
  69. ncbi request reprint Multiple myeloma: diagnosis and treatment
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 80:1371-82. 2005
    ..The current approach to the diagnosis, prognosis, and management of MM is reviewed...
  70. doi request reprint The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome
    Anita D'Souza
    Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 118:4663-5. 2011
    ..Plasma VEGF is also useful in monitoring disease activity after treatment and correlates with clinical improvements better than hematologic response...
  71. ncbi request reprint Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:257-60. 2005
    ..It was concluded that the patients with IgM MGUS should be followed indefinitely...
  72. pmc Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Eur J Haematol 80:397-406. 2008
    ..Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future...
  73. ncbi request reprint Fracture risk with multiple myeloma: a population-based study
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Bone Miner Res 20:487-93. 2005
    ..Pathologic fractures, especially of the axial skeleton, are extremely common in patients with multiple myeloma and cluster around the time of diagnosis. Osteoporotic fractures seem to be less of a problem in these patients...
  74. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  75. ncbi request reprint Myeloma and the newly diagnosed patient: a focus on treatment and management
    S Vincent Rajkumar
    Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA
    Semin Oncol 29:5-10. 2002
    ..The role of supportive care strategies for patients with bone disease, such as the use of bisphosphonates, is also discussed...
  76. ncbi request reprint Natural history and therapy of 66 patients with mixed cryoglobulinemia
    Alan H Bryce
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 81:511-8. 2006
    ..Treatment is generally directed at the underlying condition. Not all patients require treatment, and many can be followed and treated symptomatically...
  77. ncbi request reprint Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Robert A Kyle
    Mayo Clinic, Rochester, MN, USA
    Semin Oncol 30:116-20. 2003
    ..However, the panel felt that current data are inadequate to support the use of any prognostic marker to select the timing and type of therapy, and called for studies on the application of prognostic markers in WM...
  78. ncbi request reprint Fracture risk in monoclonal gammopathy of undetermined significance
    L Joseph Melton
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Bone Miner Res 19:25-30. 2004
    ..There was a 2.7-fold increase in the risk of axial fractures but no increase in limb fractures. The pathophysiologic basis for the increased axial fractures should be determined...
  79. ncbi request reprint Amyloidosis with IgM monoclonal gammopathies
    Morie A Gertz
    Dysproteinemia Clinic and the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 30:325-8. 2003
    ..We conclude that the presence of amyloid cardiomyopathy and an increased creatinine concentration had the greatest impact on survival...
  80. ncbi request reprint Neurological aspects of multiple myeloma and related disorders
    Angela Dispenzieri
    Mayo Clinic, Medicine, Rochester, Minnesota MN 55905, USA
    Best Pract Res Clin Haematol 18:673-88. 2005
    ..The authors will review the neurologic complications of MM, monoclonal gammopathy of undetermined significance (MGUS), Waldenström macroglobulinemia (WM), POEMS syndrome, amyloidosis, and cryoglobulinemia...
  81. ncbi request reprint Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice
    Jerry A Katzmann
    Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Chem 51:878-81. 2005
    ..We evaluated its diagnostic performance in clinical practice...
  82. doi request reprint Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
    R A Kyle
    Division of Hematology, Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1121-7. 2010
    ..Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months...
  83. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  84. ncbi request reprint Genomic abnormalities in monoclonal gammopathy of undetermined significance
    Rafael Fonseca
    Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:1417-24. 2002
    ..Similar translocations are found in both MGUS and MM, including t(4;14)(p16.3;q32) and t(14;16)(q32;q23). Moreover, Delta 13 is common in MGUS and unlikely to play a predominant role in the evolution of MGUS to MM...
  85. ncbi request reprint A long-term study of prognosis in monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 346:564-9. 2002
    ..A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited...
  86. ncbi request reprint Helicobacter pylori infection and monoclonal gammopathy of undetermined significance
    S Vincent Rajkumar
    Divisions of Hematology, Gastroenterology and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:706-8. 2002
    ..pylori infection (33%) by serology, breath or stool testing between patients with MGUS and those with negative monoclonal protein studies. There was no evidence of resolution of MGUS with H. pylori therapy...
  87. ncbi request reprint Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:859-66. 2004
    ..To determine the long-term outcome of patients with monoclonal gammopathy of undetermined significance (MGUS)...
  88. ncbi request reprint Conventional therapy and approach to management
    S Vincent Rajkumar
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 18:585-601. 2005
    ..We also outline the role and current indications for the use of new active agents in this disease...
  89. ncbi request reprint Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3400-7. 2004
    ..Of the 14 evaluable patients, all have had neurologic improvement or stabilization. Other features have improved substantially. PBSCT for POEMS syndrome is effective therapy but may also be associated with significant morbidity...
  90. pmc Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis
    Shaji K Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Minnesota, USA
    Am J Hematol 86:251-5. 2011
    ..It also highlights the importance of achieving at least a 90% reduction in the FLC-diff to improve the outcome of patients with light-chain AL...
  91. ncbi request reprint POEMS syndrome: definitions and long-term outcome
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2496-506. 2003
    ..Additional features of the syndrome often develop, but the complications of classic multiple myeloma rarely develop...
  92. ncbi request reprint Monoclonal gammopathy of undetermined significance
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 134:573-89. 2006
    ....
  93. ncbi request reprint Monoclonal gammopathies of undetermined significance: a review
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Immunol Rev 194:112-39. 2003
    ..MGUS may be associated with many different disorders, including lymphoproliferative diseases, leukemia, connective tissue disorders, dermatologic diseases, and neurologic disorders...
  94. pmc Multiple myeloma
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 111:2962-72. 2008
    ..We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies...
  95. doi request reprint Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Heart Lung Transplant 27:823-9. 2008
    ..Historically, patients with AL amyloidosis and overt congestive heart failure have had an ominous prognosis with median survival of approximately 6 months...
  96. ncbi request reprint Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Blood Rev 21:255-65. 2007
    ..Updated diagnostic criteria for these disorders, risk-stratification models to determine prognosis, and the current management of these two entities are discussed in this review...
  97. pmc Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
    Celine M Vachon
    Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:785-90. 2009
    ..0; 95% CI, 1.4 to 2.8) and MGUS probands (RR, 3.3; 95% CI, 2.1 to 4.8). The increased risk of MGUS in first-degree relatives of MGUS or MM patients implies shared environment and/or genetics...
  98. pmc IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 9:17-8. 2009
    ..During follow-up, 33 of the 48 patients progressed to symptomatic WM. The median time to progression was 4.6 years. The risk of progression to WM was 6% at 1 year, 39% at 3 years, and 55% at 5 years...
  99. ncbi request reprint A history of the kidney in plasma cell disorders
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Contrib Nephrol 153:5-24. 2007
    ..The kidneys are commonly injured in plasma cell dyscrasias...
  100. doi request reprint Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis
    Morie A Gertz
    Department of Hematology, Mayo Clinic, 200 First Street SW, Rochester MN, 55905, USA
    Haematologica 93:1402-6. 2008
    ..The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group...
  101. pmc Treatment of multiple myeloma: a comprehensive review
    Robert A Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Lymphoma Myeloma 9:278-88. 2009
    ..The M-protein might lead to renal failure, hyperviscosity syndrome, or through the suppression of uninvolved immunoglobulins, recurrent infections. Anemia and hypercalcemia are common complications...